The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100.
Ecaterina Ileana
No relevant relationships to disclose
Yohann Loriot
No relevant relationships to disclose
Laurence Albiges
No relevant relationships to disclose
Christophe Massard
No relevant relationships to disclose
Aurore Blesius
No relevant relationships to disclose
Mario Di Palma
No relevant relationships to disclose
Bernard J. Escudier
No relevant relationships to disclose
Pierre Blanchard
No relevant relationships to disclose
Alberto Bossi
No relevant relationships to disclose
Karim Fizazi
Consultant or Advisory Role - Astellas Pharma; Janssen-Cougar; Medivation